U.S. trial test machine that ‘reconditions’ lungs outside body

(Reuters) – A machine that ‘reconditions’ a donor’s lungs outside the body before being transplanted into a recipient is undergoing tests in the United States in the hope that it can radically improve survival rates for people with chronic respiratory diseases. The XPS, manufactured by Swedish company XVIVO Perfusion , is in clinical trials at 16 U.S. medical centers. Known as “the box,” it ventilates the lungs after removal from the donor and infuses them with a fluid mix of drugs and steroids, effectively drying them out and getting them in better shape for use in a transplant operation. The technology, which has not been used widely before, aims to increase the donor pool by reconditioning marginal lungs not suitable for transplant. “It allows the lungs to stay alive … and allows us as providers to assess the function of the organ in a unique, well-controlled environment,” said Dr. Varun Puri, an associate professor of cardiothoracic surgery at Washington University in St. Louis. The XPS, which is under test at Washington University, Duke University Medical Center, New York-Presbyterian Hospital and more than a dozen other U.S. sites, has been cleared for use in Europe and Canada and was approved for clinical trials by the U.S. Food and Drug Administration as a Humanitarian Use Device. Michele Coleman, 63, credits ‘the box’ with saving her life. A former smoker, she was diagnosed with chronic obstructive pu...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Respiratory XVIVO Perfusion Source Type: news

Related Links:

(MedPage Today) -- Tested as standalone, but potential role seen as add-on therapy
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news
COPD, which is often linked to smoking, is a progressive deterioration of lung function that involves a combination of bronchitis and emphysema symptoms.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Neurology, Nursing, Pulmonology, Research, Preventive Medicine, News, Source Type: news
Conclusion: LABA/LAMA FDCs may be helpful in improving HRQoL, but because of the heterogeneity of performed trials, strong conclusions cannot be drawn. Moreover, due to the different molecule properties, treatment schedule, and device characteristics of each FDC, a generalized judgment seems inappropriate. Pragmatic trials powered to detect real-life differences in HRQoL and head-to-head comparison are needed to guide clinical practice in terms of PROs.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
An overall reduction in the incidence of AIDS and a change in the spectrum of lung disease have been noticed in persons living with HIV (PLHIV). Our aim was to provide an epidemiological update regarding the prevalence of lung diseases in PLHIV hospitalised in France. We analysed the prevalence of lung disease in PLHIV hospitalised in France from 2007 to 2013, from the French nationwide hospital medical information database, and assessed the association between HIV and incident noninfectious disease over 4 years of follow-up. A total of 52 091 PLHIV were hospitalised in France between 2007 and 2013. Among PLHIV hospit...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Rare lung diseases Source Type: research
Publication date: Available online 16 September 2018Source: The Lancet Respiratory MedicineAuthor(s): Mona Bafadhel
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
This study is registered with ClinicalTrials.gov, number NCT02497001.FindingsBetween Aug 20, 2015, and Jan 5, 2018, 3047 patients were screened from 215 sites, and 1902 were randomly assigned to receive BGF MDI (n=640), GFF MDI (n=627), BFF MDI (n=316), or BUD/FORM DPI (n=319). Over 24 weeks, BGF MDI significantly improved FEV1 AUC0–4 versus BFF MDI (least squares mean difference 104 mL, 95% CI 77 to 131; p
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
An inhaled PDE3/4 inhibitor could serve as an add-on to standard treatments for patients with stubborn symptoms and exacerbations of chronic obstructive pulmonary disease, investigators report.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
(MedPage Today) -- And models show exacerbations further decreasing
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
Thread Starter What’s this medical device? Follow 5 hours ago 5h ago Quote: Originally Posted by hopefulDocc I volunteered today , and visited an elderly man at the hospital to keep him company . He had a big machine next to him and had a mask and loads of smo...
Source: The Student Room - Category: Universities & Medical Training Authors: Tags: Medicine Source Type: forums
More News: Cardiology | Chronic Obstructive Pulmonary | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Heart | Hospitals | Lung Transplant | Medical Devices | Perfusion | Respiratory Medicine | Smokers | Statistics | Transplant Surgery | Transplants | Washington University